Home >> Healthcare >> Targeted Drug for Leukemia Market

Global Targeted Drug for Leukemia Market Size,Trends, Growth Forecast to 2031

Category : Healthcare | Report Code : 864 | Pages : 141 | Oct 2024

Report Overview

Leukemia is a malignant clonal disease of hematopoietic stem cells. According to the degree of differentiation and maturity of leukemia cells and the natural history of the disease, leukemia is divided into two categories: acute leukemia (AL) and chronic leukemia (CL). Secondly, AL can be divided into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the mainly affected cell series. CL is divided into chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML, also known as chronic myelogenous leukemia) and rare types of leukemia. In the past decade or so, targeted drugs have made many breakthrough achievements in the clinical treatment of leukemia.

Targeted drugs for leukemia are a class of medications designed to specifically target and attack cancer cells while minimizing damage to healthy cells. These drugs work by interfering with specific molecules or pathways that are involved in the growth and survival of leukemia cells. One example of a targeted drug for leukemia is imatinib (Gleevec), which is used to treat chronic myeloid leukemia (CML) by inhibiting the activity of the BCR-ABL protein, a key driver of leukemia cell growth. Other targeted drugs, such as dasatinib, nilotinib, and ponatinib, also target the BCR-ABL protein but may be used in cases of resistance or intolerance to imatinib. Additionally, newer targeted therapies, such as venetoclax and midostaurin, target other specific molecules or pathways involved in leukemia cell proliferation, providing more treatment options for patients with different types of leukemia. Targeted drugs have revolutionized the treatment landscape for leukemia, offering improved efficacy and reduced toxicity compared to traditional chemotherapy.

As a new trend in the treatment of leukemia, gene-targeted drugs will see more research and development in the future. Although this drug still has some problems, such as high price, drug resistance, etc., with the continuous advancement of science and technology and the continuous progress of medicine, it is believed that gene-targeted drugs will become an important means of treating leukemia.

The global Targeted Drug for Leukemia market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

Analytic Insights Hub ' newest research report, the “Targeted Drug for Leukemia Industry Forecast” looks at past sales and reviews total world Targeted Drug for Leukemia sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Drug for Leukemia sales for 2024 through 2030. With Targeted Drug for Leukemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug for Leukemia industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drug for Leukemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drug for Leukemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug for Leukemia market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug for Leukemia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug for Leukemia.

Leukemia occurs most often in adults older than 55 years, but it is the most common cancer in children younger than 15 years. Among adults, the most common types are CLL (35%) and AML (32%). Among children and teens, ALL is the most common, accounting for 75% of pediatric leukemia cases.

Globally, an estimated 440,000 new cases of leukemia are diagnosed each year along with 310,000 deaths. There will be an estimated 60,000 new cases of leukemia in the United States in 2023, and more than 24,000 related deaths. Survival rates vary substantially by leukemia subtype, ranging from a current five-year relative survival rate of 27% for adults diagnosed with AML to 86% for those with CLL, and 66% for children, adolescents, and young adults diagnosed with AML to 92% for those with ALL. In 2018, there are an estimated 381,774 people living with or in remission from leukemia in the United States. As the burden of leukemia grows, there will be a corresponding increase in the demand for effective treatment options, including targeted drugs.

The development of targeted drugs has transformed the treatment landscape for leukemia, offering improved efficacy and safety compared to traditional chemotherapy. Patients and healthcare providers increasingly prefer targeted therapies due to their ability to selectively attack cancer cells while sparing healthy tissues, leading to higher demand for these drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug for Leukemia market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    Monoclonal Antibodies
    Small-Molecule Drugs

Segmentation by Application:
    Acute Myeloid Leukemia (AML)
    Chronic Myeloid Leukemia (CML)
    Acute Lymphoblastic Leukemia (ALL)
    Chronic Lymphocytic Leukemia (CLL)

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
    Novartis Pharms
    Bristol-Myers Squibb
    IL-Yang Pharms
    Pfizer
    Takeda Oncology
    Johnson & Johnson
    Gilead Sciences
    Abbvie
    Genentech
    Sanofi
    Amgen
    Roche
    GlaxoSmithKline
    AstraZeneca
    BeiGene
    Eli Lilly
    Merck

Key Questions Addressed in this Report
What is the 10-year outlook for the global Targeted Drug for Leukemia market?
What factors are driving Targeted Drug for Leukemia market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Targeted Drug for Leukemia market opportunities vary by end market size?
How does Targeted Drug for Leukemia break out by Type, by Application?

Frequently Asked Questions?

Ans - The purpose of a Targeted Drug for Leukemia market research report is to provide data-driven insights and analysis on a Targeted Drug for Leukemia market. It helps businesses understand industry trends, competition, consumer behavior, market size, growth potential, and risks, supporting strategic decision-making.

Ans - Market research reports typically include both quantitative (market size, revenue, growth rates) and qualitative (trends, consumer preferences, competitive analysis) data. It often includes industry statistics, surveys, expert opinions, historical data, and future forecasts.

Ans - The forecast period typically for Targeted Drug for Leukemia market report spans the next 5 to 10 years. It includes projected market trends, growth opportunities, and potential challenges.

Ans - Yes, Analytic Insights Hub customization services, allowing businesses to focus on specific geographies, sectors, or market segments that are relevant to them.

Ans - The report highlights major trends such as technological innovations, consumer behavior shifts, regulatory changes, or emerging markets that may impact the industry?s growth.